Israeli firm DNATix recently claimed not only the transfer of a genetic sequence using blockchain technology, but the transfer of a complete Y chromosome.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
The firm, which specializes in multiplexed protein analysis, has placed CODEX systems in 10 sites and is planning a broad launch of the platform later this year.
The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.
Backed by Andreessen Horowitz and Polaris Partners, Camp4 hopes its high-resolution gene maps can shorten and remove risk from the drug development process.
PredictImmune's test relies on a 16-marker panel run using quantitative PCR to stratify Crohn's disease and ulcerative colitis patients according to the severity of their illnesses.
The company cites flexibility and ease of use as its main selling points, and is partnering with IVD firms like Randox and R-Biopharm on assay development.
The five-year-old firm recently completed a clinical trial of the real-time PCR-based test, called ProALL-BM, on patients from a European National Registry Study.
Amplidiag CarbaR+MCR detects the main carbapenemase-producing organisms and colistin resistance markers. Novidiag Bacterial GE+ identifies the most common enteric pathogens.
The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.
